WallStreetZenWallStreetZen

NASDAQ: VRTX
Vertex Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for VRTX

Based on 15 analysts offering 12 month price targets for Vertex Pharmaceuticals Inc.
Min Forecast
$285.00-5.83%
Avg Forecast
$326.60+7.91%
Max Forecast
$365.00+20.6%

Should I buy or sell VRTX stock?

Based on 15 analysts offering ratings for Vertex Pharmaceuticals Inc.
Buy
Strong Buy
6 analysts 40%
Buy
4 analysts 26.67%
Hold
5 analysts 33.33%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their VRTX stock forecasts and price targets.

VRTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Bernstein
Bottom 47%
47
BuyInitiates Coverage On$344.00+13.66%2023-03-21
Morgan Stanley
Bottom 4%
4
HoldMaintains$285.00-5.83%2023-02-08
Piper Sandler
Bottom 15%
15
HoldMaintains$296.00-2.20%2023-02-08
Barclays
Top 18%
83
Strong BuyMaintains$342.00+13.00%2023-02-08
HC Wainwright & Co.
Top 24%
77
BuyMaintains$326.00+7.71%2023-02-08
SVB Leerink
Top 8%
93
BuyMaintains$365.00+20.60%2023-02-08
Canaccord Genuity
Top 7%
94
HoldInitiates Coverage On$311.00+2.76%2023-01-18
Jefferies
Top 12%
89
HoldDowngrades$340.00+12.34%2022-12-19
Argus Research
Top 10%
91
Strong BuyMaintains$340.00+12.34%2022-11-17Find out why
RBC Capital
Top 3%
98
HoldMaintains$288.00-4.84%2022-10-28

1 of 2

Forecast return on equity

Is VRTX forecast to generate an efficient return?
Company
N/A
Industry
-0.06%
Market
28.66%

Forecast return on assets

Is VRTX forecast to generate an efficient return on assets?
Company
N/A
Industry
0.03%

VRTX earnings per share forecast

What is VRTX's earnings per share in the next 3 years based on estimates from 11 analysts?
Avg 1 year Forecast
$13.48+3.93%
Avg 2 year Forecast
$13.59+4.78%
Avg 3 year Forecast
$14.35+10.64%
VRTX's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

VRTX revenue forecast

What is VRTX's revenue in the next 3 years based on estimates from 10 analysts?
Avg 1 year Forecast
$9.3B+4.27%
Avg 2 year Forecast
$9.9B+10.86%
Avg 3 year Forecast
$10.6B+18.35%
VRTX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

VRTX earnings growth forecast

How is VRTX forecast to perform vs Biotechnology companies and vs the US market?
Company
3.13%
Industry
10.3%
Market
19.47%
VRTX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
VRTX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
VRTX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

VRTX revenue growth forecast

How is VRTX forecast to perform vs Biotechnology companies and vs the US market?
Company
5.71%
Industry
40.73%
Market
8.78%
VRTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
VRTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

VRTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VRTX$302.66$326.60+7.91%Buy
REGN$759.76$830.00+9.25%Buy
MRNA$152.10$196.55+29.22%Buy
SGEN$199.91$185.35-7.28%Buy
BNTX$133.33$217.63+63.22%Buy
View Top Biotech Stocks

Vertex Pharmaceuticals Stock Forecast FAQ

Is Vertex Pharmaceuticals Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 15 Wall Street analysts covering (NASDAQ: VRTX) stock is to Buy VRTX stock.

Out of 15 analysts, 6 (40%) are recommending VRTX as a Strong Buy, 4 (26.67%) are recommending VRTX as a Buy, 5 (33.33%) are recommending VRTX as a Hold, 0 (0%) are recommending VRTX as a Sell, and 0 (0%) are recommending VRTX as a Strong Sell.

If you're new to stock investing, here's how to buy Vertex Pharmaceuticals stock.

What is VRTX's earnings growth forecast for 2023-2025?

(NASDAQ: VRTX) Vertex Pharmaceuticals's forecast annual earnings growth rate of 3.13% is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.3%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.47%.

Vertex Pharmaceuticals's earnings in 2023 is $3,322,000,000.On average, 11 Wall Street analysts forecast VRTX's earnings for 2023 to be $3,465,592,625, with the lowest VRTX earnings forecast at $3,221,355,756, and the highest VRTX earnings forecast at $3,918,073,561. On average, 2 Wall Street analysts forecast VRTX's earnings for 2024 to be $3,493,872,683, with the lowest VRTX earnings forecast at $3,337,046,904, and the highest VRTX earnings forecast at $3,650,698,462.

In 2025, VRTX is forecast to generate $3,689,262,178 in earnings, with the lowest earnings forecast at $3,419,316,165 and the highest earnings forecast at $3,956,637,277.

What is VRTX's revenue growth forecast for 2023-2025?

(NASDAQ: VRTX) Vertex Pharmaceuticals's forecast annual revenue growth rate of 5.71% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 40.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.78%.

Vertex Pharmaceuticals's revenue in 2023 is $8,930,700,000.On average, 10 Wall Street analysts forecast VRTX's revenue for 2023 to be $2,394,031,642,220, with the lowest VRTX revenue forecast at $2,311,097,799,725, and the highest VRTX revenue forecast at $2,494,146,905,717. On average, 9 Wall Street analysts forecast VRTX's revenue for 2024 to be $2,545,319,928,683, with the lowest VRTX revenue forecast at $2,416,145,362,518, and the highest VRTX revenue forecast at $2,672,259,856,042.

In 2025, VRTX is forecast to generate $2,717,314,102,712 in revenue, with the lowest revenue forecast at $2,492,758,611,936 and the highest revenue forecast at $2,839,806,348,142.

What is VRTX's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: VRTX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 0.03%.

What is VRTX's Price Target?

According to 15 Wall Street analysts that have issued a 1 year VRTX price target, the average VRTX price target is $326.60, with the highest VRTX stock price forecast at $365.00 and the lowest VRTX stock price forecast at $285.00.

On average, Wall Street analysts predict that Vertex Pharmaceuticals's share price could reach $326.60 by Mar 21, 2024. The average Vertex Pharmaceuticals stock price prediction forecasts a potential upside of 7.91% from the current VRTX share price of $302.66.

What is VRTX's Earnings Per Share (EPS) forecast for 2023-2025?

(NASDAQ: VRTX) Vertex Pharmaceuticals's current Earnings Per Share (EPS) is $12.97. On average, analysts forecast that VRTX's EPS will be $13.48 for 2023, with the lowest EPS forecast at $12.53, and the highest EPS forecast at $15.24. On average, analysts forecast that VRTX's EPS will be $13.59 for 2024, with the lowest EPS forecast at $12.98, and the highest EPS forecast at $14.20. In 2025, VRTX's EPS is forecast to hit $14.35 (min: $13.30, max: $15.39).

What is VRTX's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: VRTX) forecast ROE is N/A, which is considered weak.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.